CRVS

Corvus Pharmaceuticals Inc. (CRVS) | Rumor.io

Corvus Pharmaceuticals

CRVS

Attention (50-day avg)0%

Attention rank (50-day avg)#895

Bullish sentiment (50-day avg)70%

Price to earnings ratio-62.5

Market capitalization998.5M

Earnings per share-0.64

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-15.3M

Social

What share of all stock conversation is about CRVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0% 0	0% 0	0% 0

Jul 24

Corvus Pharmaceuticals' Corvilimab shows promising results in Phase 1 trials, with a 5x increase in EASI-75 scores for Cohort 3 and a 2-3x increase for Cohort 4.
The company has faced challenges, including a failed trial in refractory patients and a decline in stock price, but some analysts see potential for a quick recovery to $75-80.
Corvus' unique oral MOA and potential competition with Sanofi's Kymab could be driving factors in its stock price, with some analysts valuing the company at $30B.

Generated by AI

Sentiment

Of the messages about CRVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	87.18% +37.18	85.26% +35.59	78.07% -7.14
Bearish	0% 0	12.82% -37.18	14.74% -35.59	21.93% +7.14

Bullish· May 15

Corvus Pharmaceuticals has attracted significant new funding, with multiple institutional investors purchasing shares in the last quarter.
The company's recent data update has reinforced the potential for its novel oral regimen to deliver strong efficacy and long drug-free intervals after treatment.
The asset's price has been volatile, but long-term investors remain optimistic about its potential, citing the company's strong data and attractive valuation.

Bearish· May 15

The company's pace of advancing clinical trials and pursuing other indications is a concern, with some questioning their ability to keep up with others in the AD space.
The patent shelf life for the company's ITK inhibitor is a potential issue, with some suggesting that they need to sell or partner to enable multiple other indications.
The company's lack of approved drugs and small Phase 1 AD data may not hold up in larger trials, making it a high-risk investment in a crowded AD market.

Generated by AI

Topics

Of the messages about CRVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	91.3%	92.42%	71.22%
Controversies	0%	0%	0%	2.72%
Technical Analysis	0%	4.35%	3.03%	6.05%
Macro	0%	4.35%	1.52%	4.61%
Analysts	0%	0%	3.03%	15.18%
Earnings	0%	0%	0%	0.23%

Earnings· May 3

Corvus Pharmaceuticals, Inc. ($CRVS) beats EPS loss estimates by $0.11.
No additional earnings information is provided in this post.
No other information about the company's performance is mentioned.

Announcements· Jan 22

Corvus Pharmaceuticals, Inc. (CRVS) has priced an upsized underwritten public offering of 7,900,677 shares of its common stock at $22.15 per share, raising approximately $175 million.
The company's ITK platform, which selectively inhibits Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family, has the potential to be transformative for Th2 disease and overlap with Th17 diseases.
The successful pricing of the public offering is seen as a positive development for the company, with CRVS stock surging pre-market and reaching a new 52-week high, despite a short float of 20.6%.

Technical Analysis· Jan 21

CRVS has broken out explosively from a long accumulation range, clearing all prior resistance with a vertical impulse and strong momentum expansion.
The trend has shifted firmly bullish, with former supply in the 9.50–10.00 zone decisively flipping into structural support, and the next support / consolidation for the next 2-3 weeks expected to be around $18.
The stock is vulnerable to volatility and may experience a sharp pullback or consolidation toward $15–16 or even $12–13, but continuation remains favored while price holds above $18.00–19.00.

Generated by AI

Community

Of the messages about CRVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.19%	86.4%	94.04%	74.94%
Newcomers	5.81%	13.6%	5.96%	25.06%

Regulars· Jul 24

Corvus Pharmaceuticals' oral MOA makes it as compelling as NKTR's new MOA, with both having the potential to be first to market.
The overlap of Corvus' oral MOA data with Kymab's original AMLitelimab data shows promising results, with Cohort 3 and 4 EASI-75 metrics indicating ~5x and ~2-3x better outcomes, respectively.
Corvus' trial in refractory patients who failed dupilumab, OX40, and JAK inhibitors may be a key area of focus, with the regulars comparing it to Kymab's original AMLitelimab data and speculating about the potential for Corvus to meet or exceed Dupi's performance.

Newcomers· May 18

The newcomer analysts are modeling $1.5B in peak sales for soquelitinib in Atopic Dermatitis (AD) alone, and are optimistic about the peak market share for an effective, oral, highly tolerable, "immune rebalancing" drug.
The models assume that the stock will reach peak sales in 2038, with a launch in 2032 and a long term operating expense in 2043, using a 11.5% discount rate and a 20% probability of success.
The newcomer analysts are optimistic about the stock's potential, despite some models suggesting it may be overvalued, and are considering adding to their positions due to the dip being a shakeout and the upcoming Phase 3 interim data in 2026.

Generated by AI

News

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and...

1mo agoBarchart.com

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

1mo agoSeeking Alpha

Also Discussed

Investors talking about CRVS also mention

#	Name	Attention
1	Zivo Bioscience Inc.ZIVO	0%0
2	Nektar TherapeuticsNKTR	0.08%+0.03
3	DAWN - Day One Biopharmaceuticals, Inc.	——
4	Kymera Therapeutics Inc.KYMR	0%0
5	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
6	TERN - Terns Pharmaceuticals, Inc.	——
7	IDEAYA Biosciences Inc.IDYA	0%-0.01
8	ImageneBio, Inc.IKNA	0%0
9	RAPT - RAPT Therapeutics, Inc.	——
10	Apogee Therapeutics, Inc. - Common StockAPGE	0%0

Corvus Pharmaceuticals Inc.

Healthcare
Biotechnology

Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation, signaling, and function. Its pipeline includes soquelitinib, a lead ITK inhibitor, along with other programs such as anti-CD73, A2AR, A2BR, and anti-CXCR2 approaches. The company’s research spans solid tumors, T-cell lymphomas, autoimmune disorders, allergic conditions, and infectious diseases. Corvus Pharmaceuticals Inc. is positioned in the biotechnology sector as a development-stage company advancing novel drug candidates through clinical evaluation, with a business model built around drug discovery, clinical development, and scientific partnerships.

Website

Location

901 Gateway Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about CRVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0% 0	0% 0	0% 0

Jul 24

Corvus Pharmaceuticals' Corvilimab shows promising results in Phase 1 trials, with a 5x increase in EASI-75 scores for Cohort 3 and a 2-3x increase for Cohort 4.
The company has faced challenges, including a failed trial in refractory patients and a decline in stock price, but some analysts see potential for a quick recovery to $75-80.
Corvus' unique oral MOA and potential competition with Sanofi's Kymab could be driving factors in its stock price, with some analysts valuing the company at $30B.

Generated by AI

Sentiment

Of the messages about CRVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	87.18% +37.18	85.26% +35.59	78.07% -7.14
Bearish	0% 0	12.82% -37.18	14.74% -35.59	21.93% +7.14

Bullish· May 15

Corvus Pharmaceuticals has attracted significant new funding, with multiple institutional investors purchasing shares in the last quarter.
The company's recent data update has reinforced the potential for its novel oral regimen to deliver strong efficacy and long drug-free intervals after treatment.
The asset's price has been volatile, but long-term investors remain optimistic about its potential, citing the company's strong data and attractive valuation.

Bearish· May 15

The company's pace of advancing clinical trials and pursuing other indications is a concern, with some questioning their ability to keep up with others in the AD space.
The patent shelf life for the company's ITK inhibitor is a potential issue, with some suggesting that they need to sell or partner to enable multiple other indications.
The company's lack of approved drugs and small Phase 1 AD data may not hold up in larger trials, making it a high-risk investment in a crowded AD market.

Generated by AI

Topics

Of the messages about CRVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	91.3%	92.42%	71.22%
Controversies	0%	0%	0%	2.72%
Technical Analysis	0%	4.35%	3.03%	6.05%
Macro	0%	4.35%	1.52%	4.61%
Analysts	0%	0%	3.03%	15.18%
Earnings	0%	0%	0%	0.23%

Earnings· May 3

Corvus Pharmaceuticals, Inc. ($CRVS) beats EPS loss estimates by $0.11.
No additional earnings information is provided in this post.
No other information about the company's performance is mentioned.

Announcements· Jan 22

Corvus Pharmaceuticals, Inc. (CRVS) has priced an upsized underwritten public offering of 7,900,677 shares of its common stock at $22.15 per share, raising approximately $175 million.
The company's ITK platform, which selectively inhibits Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family, has the potential to be transformative for Th2 disease and overlap with Th17 diseases.
The successful pricing of the public offering is seen as a positive development for the company, with CRVS stock surging pre-market and reaching a new 52-week high, despite a short float of 20.6%.

Technical Analysis· Jan 21

CRVS has broken out explosively from a long accumulation range, clearing all prior resistance with a vertical impulse and strong momentum expansion.
The trend has shifted firmly bullish, with former supply in the 9.50–10.00 zone decisively flipping into structural support, and the next support / consolidation for the next 2-3 weeks expected to be around $18.
The stock is vulnerable to volatility and may experience a sharp pullback or consolidation toward $15–16 or even $12–13, but continuation remains favored while price holds above $18.00–19.00.

Generated by AI

Community

Of the messages about CRVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.19%	86.4%	94.04%	74.94%
Newcomers	5.81%	13.6%	5.96%	25.06%

Regulars· Jul 24

Corvus Pharmaceuticals' oral MOA makes it as compelling as NKTR's new MOA, with both having the potential to be first to market.
The overlap of Corvus' oral MOA data with Kymab's original AMLitelimab data shows promising results, with Cohort 3 and 4 EASI-75 metrics indicating ~5x and ~2-3x better outcomes, respectively.
Corvus' trial in refractory patients who failed dupilumab, OX40, and JAK inhibitors may be a key area of focus, with the regulars comparing it to Kymab's original AMLitelimab data and speculating about the potential for Corvus to meet or exceed Dupi's performance.

Newcomers· May 18

The newcomer analysts are modeling $1.5B in peak sales for soquelitinib in Atopic Dermatitis (AD) alone, and are optimistic about the peak market share for an effective, oral, highly tolerable, "immune rebalancing" drug.
The models assume that the stock will reach peak sales in 2038, with a launch in 2032 and a long term operating expense in 2043, using a 11.5% discount rate and a 20% probability of success.
The newcomer analysts are optimistic about the stock's potential, despite some models suggesting it may be overvalued, and are considering adding to their positions due to the dip being a shakeout and the upcoming Phase 3 interim data in 2026.

Generated by AI

Corvus Pharmaceuticals

Social

Jul 24

Bullish· May 15

Bearish· May 15

Earnings· May 3

Announcements· Jan 22

Technical Analysis· Jan 21

Regulars· Jul 24

Newcomers· May 18

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

Also Discussed

Corvus Pharmaceuticals Inc.

Company Information

Location

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

Also Discussed

Social

Jul 24

Bullish· May 15

Bearish· May 15

Earnings· May 3

Announcements· Jan 22

Technical Analysis· Jan 21

Regulars· Jul 24

Newcomers· May 18